LIQUID BIOPSY AND ctDNA TESTING WITH CRYSTAL DIGITAL PCR™
Providing sensitivity for patient samples through ctDNA testing
Liquid biopsies are a minimally invasive sampling approach to overcome the heterogeneity of tumors and represent a valuable source of circulating tumor DNA (ctDNA) for oncological biomarker analysis. These samples contain a wealth of genetic information that can be used to inform disease diagnosis, guide therapeutic actions, monitor treatment effectiveness, and detect disease relapse.
The use of ctDNA as a surrogate for tissue DNA has become increasingly popular, and advances in the detection and characterization of ctDNA have enable liquid biopsy assay integration into clinical practice.
ctDNA measurements require a highly sensitive and reliable detection technology to quantify often low-level genetic aberrations within a high background of wild-type sequences, and digital PCR has emerged as a powerful technology for the next-generation analysis of liquid biopsies.
From sample extraction to analysis
The Nio+ system offers a fast, easy-to-use platform for quantification of genetic targets with the highest multiplexing available on the market today. When coupled with a sample preparation platform such as the Maxwell® RSC instruments from Promega, users are provided with a seamless end-to-end workflow – from sample preparation to analysis.
Detect genetic mutations across oncological indications
Stilla provides digital PCR kits out-of-the-box, as well as custom assay design services in order to help researchers detect and quantify genes across multiple cancer indications through a liquid biopsy test.
EGFR mutation detection
EGFR mutation detection in NSCLC FFPE samples using Crystal Digital PCR® and Nio™+ system
Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR
High multiplex, ultrasensitive EGFR detection using the EGFR 6-color Crystal Dgital PCR Kit
Detection of EGFR mutations in plasma cfDNA and CTCs of NSCLC patients using Crystal Digital PCR™
Detect EGFR mutations in 6-colors with the EGFR 6-color Crystal Digital PCR Kit
ESR1 mutation detection
ESR1 mutation detection in FFPE and Plasma DNA of breast cancer patients using Crystal Digital PCR® and Nio™+.
Other indications
Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma
A detection of hypermethylated circulating tumor DNA by Crystal Digital PCR
An ultrasensitive high-plex assay detection 24 PIK3CA mutations using SAGAsafe technology and 6-color Crystal Digital PCR
Robust sample recovery post-digital PCR for downstream genomic application
education
Getting started with digital PCR
From custom assay design services to onsite training, Stilla has the knowledge and expertise to help researchers get started on their workflow. Stilla technologies has compiled several statistical tools to help get your started with your digital PCR assays, including:
For Research Use Only. Not for use in diagnostic procedures.